OncoSec Medical Inc (ONCSQ)

[lasers]

Titan V Excellent DD for the $ONCS shareholders to read.

TLSR: Did you maintain your $1.20/share target price on OncoSec when you updated your coverage—which, since the recent Financial Industry Regulatory Authority (FINRA)-approved 1-for-20 reverse stock split, equates to a $24/share target?

RS: Yes, we did. The company has stated it has sufficient capital through 2017. It has $30.7M in cash as of its most recent quarter. OncoSec has stated it will have a number of trials that will begin enrolling this quarter—three specifically—and the company anticipates enrollment will be completed for all three within 12 months. We look forward to data from those trials as soon as they're available.